Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Regeneron and SillaJen evaluate oncolytic virus combo therapy for kidney cancer

Executive Summary

Regeneron Pharmaceuticals Inc. and SillaJen Corp. have planned a Phase Ib dose-escalation study as part of a trial collaboration evaluating the combination of Regeneron’s PD-1 inhibitor REGN2810 and SillaJen’s oncolytic vaccinia virus Pexa-Vec (pexastimogene devacirepvec) for patients with previously treated metastatic or unresectable renal cell carcinoma.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Trial Collaborations
    • R&D (No Licensing)

Related Companies